Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.
Saad Z. Usmani, MD, FACP, chief of the Plasma Cell Disorders Program and director of Clinical Research in Hematologic Malignancies, at the Levine Cancer Institute, Atrium Health, discusses current challenges in patients with high-risk multiple myeloma. space.
High-risk patients make up a small percentage of the total population of patients with myeloma that are included in many frontline, randomized phase 3 studies, says Usmani. Moreover, trial enrollment has not been robust enough to observe clinical benefit within this patient population. As such, there is no established standard of care.
In 2011, the National Cancer Institute Myeloma Steering Committee identified high-risk features in multiple myeloma based upon the information available at the time, says Usmani. Moreover, this led to the first high-risk clinical trial for patients with newly diagnosed and high-risk disease.